|
(Princeton, New Jersey) U.S. pharmaceutical firms Bristol-Myers Squibb
(NYSE:BMY)
and Gilead Sciences are seeking Health Canada approval to sell a once-per-day
treatment for HIV-1 infection in adults
in Canada.
Bristol-Myers Squibb and Gilead (NASDAQ:GILD) said Friday they have reached
an agreement to commercialize Atripla in Canada that follows a five-year
partnership selling the drug in the United States.
Atripla - a combination of 600 milligrams
efavirenz, 200 mg emtricitabine and
300 mg tenofovir disoproxil fumarate - is the first once-daily single tablet
regimen for HIV intended as a stand-alone therapy or in combination with other
antiretrovirals, the companies said in a release.
The treatment received U.S. Food & Drug Administration approval on July
12.
Bristol-Myers Squibb and Gilead will provide combined funding and sales
representatives to promote Atripla in Canada, with potential revenues recorded
by Gilead and an undisclosed percentage recorded by Bristol-Myers Squibb.
``We are pleased to have finalized our agreement for Canada, and are working
expeditiously to complete the regulatory filing for Atripla with Health
Canada,'' Gilead president and CEO John Martin said in a statement.
``We recognize the need for access to Atripla, the first once-daily single
tablet regimen, and are working to make it available to all patients who need it
as quickly as possible.''
©365Gay.com 2006
|
Entertainment
